---
title: "Rhythm Pharmaceuticals CFO Hunter C. Smith Reports Sale of Common Shares"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/275183344.md"
datetime: "2026-02-06T23:38:58.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/275183344.md)
  - [en](https://longbridge.com/en/news/275183344.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/275183344.md)
---

> Supported Languages: [简体中文](https://longbridge.com/zh-CN/news/275183344.md) | [繁體中文](https://longbridge.com/zh-HK/news/275183344.md)


# Rhythm Pharmaceuticals CFO Hunter C. Smith Reports Sale of Common Shares

Hunter C. Smith, Chief Financial Officer of Rhythm Pharmaceuticals Inc., reported a disposal of common shares of the company. The full filing can be accessed through the link below. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Rhythm Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-26-011651), on February 06, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here

### Related Stocks

- [State Street® SPDR® S&P® Biotech ETF (XBI.US)](https://longbridge.com/en/quote/XBI.US.md)
- [ALPS Medical Breakthroughs ETF (SBIO.US)](https://longbridge.com/en/quote/SBIO.US.md)
- [Invesco Biotechnology & Genome ETF (PBE.US)](https://longbridge.com/en/quote/PBE.US.md)
- [State Street®HlthCrSelSectSPDR®ETF (XLV.US)](https://longbridge.com/en/quote/XLV.US.md)
- [VanEck Biotech ETF (BBH.US)](https://longbridge.com/en/quote/BBH.US.md)
- [iShares Biotechnology ETF (IBB.US)](https://longbridge.com/en/quote/IBB.US.md)
- [Rhythm Pharmaceuticals, Inc. (RYTM.US)](https://longbridge.com/en/quote/RYTM.US.md)
- [ARK Genomic Revolution ETF (ARKG.US)](https://longbridge.com/en/quote/ARKG.US.md)
- [ProShares Ultra Nasdaq Biotechnology (BIB.US)](https://longbridge.com/en/quote/BIB.US.md)
- [First Trust NYSE Arca Biotech ETF (FBT.US)](https://longbridge.com/en/quote/FBT.US.md)
- [iShares US Pharmaceuticals ETF (IHE.US)](https://longbridge.com/en/quote/IHE.US.md)
- [Vanguard Health Care ETF (VHT.US)](https://longbridge.com/en/quote/VHT.US.md)

## Related News & Research

- [Intensity Therapeutics, Inc. Provides Update on the Phase 2 Presurgical Triple-Negative Breast Cancer INVINCIBLE-4 Study | INTS Stock News](https://longbridge.com/en/news/278874097.md)
- [bioAffinity Launches Major Lung Cancer Detection Study](https://longbridge.com/en/news/278565253.md)
- [Clene 2025 net loss narrows as expenses fall](https://longbridge.com/en/news/278880252.md)
- [Prelude Therapeutics reports $99.5 mln net loss for 2025](https://longbridge.com/en/news/278542482.md)
- [Galecto Rebrands as Damora Therapeutics with New Ticker](https://longbridge.com/en/news/278556054.md)